South Korea · Delayed Price · Currency is KRW CG MedTech Statistics
Total Valuation
CG MedTech has a market cap or net worth of KRW 165.21 billion. The enterprise value is 152.48 billion.
| Market Cap | 165.21B |
| Enterprise Value | 152.48B |
Important Dates
The last earnings date was Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CG MedTech has 103.26 million shares outstanding. The number of shares has increased by 75.42% in one year.
| Current Share Class | 103.26M |
| Shares Outstanding | 103.26M |
| Shares Change (YoY) | +75.42% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.26% |
| Owned by Institutions (%) | n/a |
| Float | 60.97M |
Valuation Ratios
The trailing PE ratio is 49.08.
| PE Ratio | 49.08 |
| Forward PE | n/a |
| PS Ratio | 3.62 |
| PB Ratio | 1.84 |
| P/TBV Ratio | 2.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 274.36 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 29.02, with an EV/FCF ratio of -33.20.
| EV / Earnings | 39.62 |
| EV / Sales | 3.34 |
| EV / EBITDA | 29.02 |
| EV / EBIT | 45.00 |
| EV / FCF | -33.20 |
Financial Position
The company has a current ratio of 2.79, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.79 |
| Quick Ratio | 1.62 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.89 |
| Debt / FCF | -1.01 |
| Interest Coverage | 18.16 |
Financial Efficiency
Return on equity (ROE) is 4.79% and return on invested capital (ROIC) is 4.46%.
| Return on Equity (ROE) | 4.79% |
| Return on Assets (ROA) | 2.08% |
| Return on Invested Capital (ROIC) | 4.46% |
| Return on Capital Employed (ROCE) | 3.43% |
| Weighted Average Cost of Capital (WACC) | 0.53% |
| Revenue Per Employee | 379.93M |
| Profits Per Employee | 32.07M |
| Employee Count | 120 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 1.92 |
Taxes
In the past 12 months, CG MedTech has paid 184.15 million in taxes.
| Income Tax | 184.15M |
| Effective Tax Rate | 4.59% |
Stock Price Statistics
The stock price has increased by +45.59% in the last 52 weeks. The beta is -0.69, so CG MedTech's price volatility has been lower than the market average.
| Beta (5Y) | -0.69 |
| 52-Week Price Change | +45.59% |
| 50-Day Moving Average | 1,248.50 |
| 200-Day Moving Average | 1,065.93 |
| Relative Strength Index (RSI) | 72.52 |
| Average Volume (20 Days) | 3,457,548 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CG MedTech had revenue of KRW 45.59 billion and earned 3.85 billion in profits. Earnings per share was 32.60.
| Revenue | 45.59B |
| Gross Profit | 20.22B |
| Operating Income | 3.37B |
| Pretax Income | 4.01B |
| Net Income | 3.85B |
| EBITDA | 5.24B |
| EBIT | 3.37B |
| Earnings Per Share (EPS) | 32.60 |
Balance Sheet
The company has 17.53 billion in cash and 4.66 billion in debt, with a net cash position of 12.88 billion or 124.69 per share.
| Cash & Cash Equivalents | 17.53B |
| Total Debt | 4.66B |
| Net Cash | 12.88B |
| Net Cash Per Share | 124.69 |
| Equity (Book Value) | 89.88B |
| Book Value Per Share | 869.05 |
| Working Capital | 27.48B |
Cash Flow
In the last 12 months, operating cash flow was 602.18 million and capital expenditures -5.19 billion, giving a free cash flow of -4.59 billion.
| Operating Cash Flow | 602.18M |
| Capital Expenditures | -5.19B |
| Free Cash Flow | -4.59B |
| FCF Per Share | -44.47 |
Margins
Gross margin is 44.36%, with operating and profit margins of 7.40% and 8.44%.
| Gross Margin | 44.36% |
| Operating Margin | 7.40% |
| Pretax Margin | 8.80% |
| Profit Margin | 8.44% |
| EBITDA Margin | 11.49% |
| EBIT Margin | 7.40% |
| FCF Margin | n/a |
Dividends & Yields
CG MedTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -75.42% |
| Shareholder Yield | -75.42% |
| Earnings Yield | 2.33% |
| FCF Yield | -2.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 5, 2022. It was a forward split with a ratio of 5.
| Last Split Date | Aug 5, 2022 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
CG MedTech has an Altman Z-Score of 2.83 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.83 |
| Piotroski F-Score | 6 |